CAR T Cell Therapy: One of the Most Promising Treatments for Blood Cancer
CAR T Cell Therapy: One of the Most Promising Treatments for Blood Cancer
Chimeric antigen receptor or CAR T cell therapy uses the body’s own immune system to fight cancer. In this episode, we will learn about the newest treatment of blood cancer— CAR T cell therapy.
But first, please like the video and subscribe to our channel for more such content in the future. Push the bell icon to receive updates every time we upload a video.
A clinical trial of CAR T cell therapy has shown very positive results. Full recovery of almost 92 percent was seen in the end stages of the clinical trials of patients suffering from Acute Lymphocytic Leukemia.
What is CAR T cell therapy?
A type of cancer immunotherapy, CAR T cell therapy uses the body’s own T cells to fight cancerous cells. Cart T cells are genetically modified in a lab, which enables them to locate cancer cells easily.
CAR T cell therapy can be used for various types of cancers even when other treatments fail. CAR T cell therapy has shown positive results in the following types of cancers:
- Leukemia
- Multiple Myeloma
- Lymphoma
Faculty members at Penn were encouraged to track and harness the power of the immune system to fight cancer after CAR T cell therapy by the FDA.
Assistant professor of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine, Avery Posey, said, “An approval like that makes what you’re working on more of a reality. It brings a new perspective, showing that your work is more than basic research and can actually become drugs that impact patients’ lives. That’s a real motivator to keep pushing forward.”
An article published in Penn Medicine News mentions the following:
“The volume of new cancer treatments makes sense, says Abramson Cancer Center (ACC) Director Robert Vonderheide, MD, DPhil, attributing the flurry of new cancer drug approvals to a recent ‘explosion’ in knowledge about cancer biology.
‘Much of that knowledge is about the immune system’s ability to attack cancer, which people seriously doubted until about 20 years ago. As soon as we had a clinical validation for this Achilles heel in cancer, the dam burst for ideas about other ways to exploit that vulnerability to come forward,’ he says. ‘The first drug that came out to activate the immune system inspired the rest of the field to find the next drug, and the one after that. We as a field have moved from serendipity and empiricism to science-driven drug design.’”
How did you find this information? Please mention this in the comments section. We would also like to know the kind of content you want to watch, and we will try to create it for you. For more news and updates, follow Airr News.
#CarTCellTherapy #ImmunoTherapy #Dostarlimab #Cancer #Leukemia #Lymphoma #MultipleMyeloma #CancerSurvival #CancerFree #Chemotherapy #ImmuneSystem #TCells #BloodCells #LaboratoryModified #ClinicalTrial #Health #cancertherapy #cancerpatients #blood #india #airrnews
